Top Markets
#1 Islamic Coin Islamic Coin +158.12%
#2 Glidr Glidr +58.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#4 Cryptopia Cryptopia +15.19%
#5 Victoria VR Victoria VR +13.77%
#6 Palladium Network Palladium Network +9.99%
#7 COTI COTI +6.95%
#8 龙虾 (Lobster) 龙虾 (Lobster) +6.45%
#9 DMT-NAT DMT-NAT +6.37%
#10 Movement Movement +6.02%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc.

USRM
Classifica tra le azioni #41992
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and... U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
Prezzo delle azioni
$0.00001
Ultima sincronizzazione: 2026-08-07
Capitalizzazione di mercato
$6.42K
Variazione (1 giorno)
-90.00%
Variazione (1 anno)
-90.00%
Paese
US
Scambia U.S. Stem Cell, Inc. (USRM)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per U.S. Stem Cell, Inc. (USRM)
L’azione U.S. Stem Cell, Inc. (simbolo: USRM) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 13, 2026.
Una quota di USRM acquistata prima di Aug 13, 2026 equivale oggi a 0 quote di USRM.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE